Background
==========

Hyperlactatemia is a common phenomenon following cardiac surgeries. Although it is frequently used as a marker of observed tissue hypoxia, lactate metabolism during the perioperative period is complex and dynamic. Early-onset hyperlactatemia is defined as developing in the operating room or very early following Intensive Care Unit (ICU) admission and it usually does not spontaneously resolve within 24 h after surgery. *De novo* hyperlactatemia, which is not present up to 6 h following ICU admission, is accompanied by normal cardiac output and absence of impaired tissue oxygen delivery and is observed in approximately 15--20% of cardiosurgical patients \[[@b1-anntransplant-25-e920288]\]. Previous studies, comparing survivors *vs.* non-survivors following non-transplant cardiac surgeries, have indicated that higher lactate levels upon ICU admission (2--3 mmol/l), or within early postoperative hours (3--4 mmol/l), are associated with increased perioperative risk and prolonged hospital stay \[[@b2-anntransplant-25-e920288]--[@b5-anntransplant-25-e920288]\].

Nevertheless, such analysis, which would define the threshold for increased postoperative risk of major complications, has never been performed in patients undergoing heart transplantation (HTX). Among these individuals, higher postoperative levels are expected, as end-organ hypoperfusion, need for inotropic and vasopressor support, and low cardiac output syndrome are commonly observed, and results from studies of other cardiac surgeries may not be comparable.

Therefore, this study aimed to assess the prognostic value and clinical usefulness of postoperative serum lactate level measurements for in-hospital mortality prediction following HTX.

Material and Methods
====================

Forty-six consecutive patients who underwent HTX in the Department of Cardiovascular Surgery and Transplantology between 2010 and 2015 were enrolled into this retrospective analysis. All patients who underwent HTX within the analyzed period were included into the analysis. The majority of the study group were males (89.1%), with a mean age of 48.7±11.7 years, and were qualified for HTX due to dilated cardiomyopathy (73.9%) ([Table 1](#t1-anntransplant-25-e920288){ref-type="table"}). Serum lactate level measurements within the first 48 h after HTX were obtained from arterial blood gas analyses routinely assessed every 6 h. The observation made upon ICU admission was defined as the *zero* serum lactate measurement *(Lac 0*). Lactate clearance was calculated based on the equation: (\[lactate~initial~--lactate~delayed~\]/lactate~initial~×100) \[[@b6-anntransplant-25-e920288]\], and was determined for each patient individually throughout 3 different time frames: the first 24-h period (*Lac~clear~0--24*) and the second 24-h period (*Lac~clear~24--48*), and the first 48 h after surgery (*Lac~clear~0--48*). The threshold for hyperlactatemia was set at \>1.6 mmol/L, based on internal laboratory standardization. The end-point was determined as death during hospitalization following HTX.

The study was approved by the Jagiellonian University Bioethics Committee (122.6120.74.2017). Verbal consent was obtained from all living patients. The study was funded by a grant from Jagiellonian University Medical College (K/ZDS/007226).

Statistical analysis
--------------------

Statistical analysis was performed with IBM^®^ SPSS^®^ Statistics 25. Normality of data distribution was tested using the Shapiro-Wilk test. Continuous variables are presented as means and standard deviation (±SD) or medians and interquartile ranges (IQR). For categorical variables, numbers and proportions are reported. The non-parametric test for independent samples (Mann-Whitney U test) was used to assess differences between groups. Univariate regression analysis followed by multivariate regression were performed to explore the relationship between various serum lactate measurements and in-hospital mortality. All available serum lactate level measurements were included into the univariate analysis. Receiver operating characteristic (ROC) curves and respective areas under the ROC curves (AUC) were constructed to identify the optimal marker and cut-off value.

Results
=======

The ICU admission serum lactate level (*Lac 0*) differed between the deceased and survivors (7.6 *vs.* 4.3 mmol/L; p=0.000), with no differences observed in the lactate clearance parameters throughout the observation ([Figure 1](#f1-anntransplant-25-e920288){ref-type="fig"}). In the multivariate regression model, from all analyzed lactate parameters, only the ICU admission serum lactate level (*Lac 0*) independently predicted in-hospital mortality (OR 1.94 95% CI \[1.09--3.43\]; p=0.024) ([Figure 2](#f2-anntransplant-25-e920288){ref-type="fig"}). The ROC for in-hospital mortality was constructed for the ICU admission serum lactate level (*Lac 0*), and the optimal cut-off value was estimated to be 7.0 mmol/L (67% sensitivity, 90% specificity) ([Figure 3](#f3-anntransplant-25-e920288){ref-type="fig"}).

Discussion
==========

Early-onset hyperlactatemia is strongly associated with postoperative adverse events, presumably due to the complex pathogenesis, which combines hypoxic (circulatory or microcirculatory shock) and non-hypoxic (accelerated aerobic metabolism) mechanisms \[[@b1-anntransplant-25-e920288]\]. Because it reflects the status of tissue perfusion, it is used to predict early outcome in terms of mortality, morbidity, and ICU length of stay following cardiosurgical procedures \[[@b2-anntransplant-25-e920288]--[@b5-anntransplant-25-e920288]\].

Nevertheless, adapting thresholds for serum lactate levels corresponding with higher postoperative risk, established for other cardiac surgeries, will not be clinically efficient, as serum lactate levels observed early after HTX are higher, even among the survivors ([Figure 1](#f1-anntransplant-25-e920288){ref-type="fig"}). However, to date, only 2 studies on postoperative hyperlactatemia among heart transplant recipients have been published. Extreme hyperlactatemia was defined by Hsu et al. as the serum lactate level over 15 mmol/L and was reported to have a prevalence rate of 20.7% in patients after HTX. Despite the further serum lactate level decrease below 4 mmol/L, all patients died either while in the hospital (33.3%) or within 5 years after HTX (66.6%) \[[@b7-anntransplant-25-e920288]\]. In another study, the cut-off level for postoperative hyperlactatemia was set according to the guidelines for severe sepsis and septic shock treatment (4 mmol/L). Based on this estimation, postoperative hyperlactatemia was observed among two-thirds of the recipients, but no in-hospital deaths were reported \[[@b8-anntransplant-25-e920288]\]. Both of these studies only evaluated the fact of reaching the predefined threshold, which had never previously been defined for heart transplant recipients. Based on the present study, which sought to define the threshold, the cut-off value of 7 mmol/L should be considered relevant for in-hospital mortality prediction ([Figure 3](#f3-anntransplant-25-e920288){ref-type="fig"}).

Although single serum lactate concentration is potentially useful, it does not contain directional information about the patient's improvement or deterioration. Sequential serum lactate level measurements, which have been assessed for patients undergoing coronary artery bypass-grafting, mitral valve surgery, or Norwood procedure, showed that high lactate concentration is associated with inability to clear blood lactate levels, and have highest predictive value for adverse outcome \[[@b9-anntransplant-25-e920288]--[@b11-anntransplant-25-e920288]\]. However, among heart transplant recipients, no such association was found for lactate utilization ability and, unlike other cardiosurgical populations, hyperlactatemia was not combined with low lactate clearance values ([Figure 1](#f1-anntransplant-25-e920288){ref-type="fig"}). Although metabolic pathways that provide lactate resolution are widely described in the literature \[[@b1-anntransplant-25-e920288]\], there is still limited knowledge regarding clinical features that might alter individual ability to clear serum lactate.

The greatest study limitation is the small sample size, which did not allow us to test the applicability of the estimated cut-off value. However, we believe that setting a threshold to be tested and further investigated by other researchers will allow such data to be produced in the future.

Conclusions
===========

Serum lactate level measurement upon ICU admission can be used as a predictive parameter for in-hospital mortality among heart transplant recipients. Values greater than 7.0 mmol/L can determine in-hospital mortality with 90% specificity.
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###### 

Baseline characteristics.

  Variable                         Analyzed population; N=46
  -------------------------------- ---------------------------
  Age, years                       48.7±11.7
  Male sex, n (%)                  41 (89.1)
  Dilated cardiomyopathy, n (%)    34 (73.9)
  Ischemic cardiomyopathy, n (%)   12 (26.1)
  Dyslipidemia, n (%)              16 (34.8)
  Hypertension, n (%)              21 (45.7)
  Diabetes, n (%)                  12 (26.1)

Data shown as mean±SD or as median (IQR), or number (percentage).
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